Ziarco Pharma Ltd - Phase 2a Psoriasis Study Initiated with Ziarco’s Lead Compound ZPL-389
Ziarco Pharma Ltd., a biopharmaceutical company focusing on the development of novel drugs against inflammatory skin disorders, today announced that dosing has started in a Phase 2a proof of concept study in moderate to severe psoriasis with ZPL-389. The Ziarco study commenced on schedule with results expected in H1 2017.
ZPL-389, a wholly-owned Ziarco drug, is a potent, selective histamine H4 receptor antagonist. The psoriasis Phase 2a clinical trial was opened under an IND at both US and European sites including the UK. It is a randomised, double blind, placebo controlled study in moderate to severe psoriasis patients. Subjects are being randomised to receive either oral 30 mg ZPL-389 once daily or placebo once daily for 12 weeks, with the primary endpoint of percentage change from baseline in the psoriasis area severity index (PASI) and secondary endpoint that includes improvement in the investigator’s global assessment (IGA). For more information about the study please visit https://clinicaltrials.gov/ct2/show/NCT02618616.
In addition, recruitment for a Phase 2a trial of ZPL-389 in moderate to severe atopic dermatitis has been completed and this will read out in Q2 2016.
Commenting on the start of dosing, Mike Grey, Executive Chairman of Ziarco, said: “We believe ZPL-389 has the potential to provide a first-in-class, safe and effective treatment for highly-prevalent, poorly-served inflammatory skin diseases. We are pleased to have initiated clinical Phase 2a studies with ZPL-389 in both atopic dermatitis and psoriasis and are anticipating the outcome of the atopic dermatitis study in the next few months.”
Dr. Dorota Wielowieyska-Szybińska, the study’s Principal Investigator, added: “Ziarco’s ZPL-389 is a new oral drug which has real potential to make a significant difference to the treatment of moderate to severe psoriasis patients. I am eager to see the study outcome as current oral treatments are often poorly tolerated and not indicated for long term use.”
US and EU5 estimates of psoriasis prevalence range from 2-4%. Plaque psoriasis accounts for approx. 90% of the psoriasis population. In the US, it is estimated that direct costs on health care approach ~$7B and the most severe patients (~10%) are typically treated with systemic biologics. Current treatments for the remaining 90% are suboptimal, both in terms of efficacy and safety.1
Ziarco is a clinical-stage biotechnology company developing innovative therapeutics targeting dermatological and inflammatory diseases. ZPL-389, the Company’s lead compound, is an oral histamine H4 receptor antagonist, currently in two Phase 2a studies: the first in atopic dermatitis is fully recruited and will read out in Q2 2016; and the second has been initiated in moderate to severe psoriasis patients and is expected to be fully recruited in Q1 2017.
ZPL-521, a topical cPLA2 inhibitor, is being developed for moderate to severe inflammatory skin diseases and is targeted to start a clinical study in atopic dermatitis in mid-2016, with data due in Q1 2017.
Ziarco’s investors include Biotechnology Value Fund L.P. and other affiliates of BVF Partners L.P., Pfizer Venture Investments, New Enterprise Associates, Lundbeckfond Ventures and Amgen Ventures. Founded in October 2012, the Company is based in Discovery Park, Sandwich, UK. For more information please visit www.ziarcopharma.com.
1 Yeung et al. Psoriasis severity and the prevalence of major medical comorbidities: a population-based study. JAMA Dermatol. 2013 October 1; 149(10): 1173–1179
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Edgewater Networks Announces Event Sponsorship of BroadSoft Connections 201720.10.2017 21:00 | Pressemelding
Edgewater Networks, Inc., the industry leader in Network Edge Orchestration, announced today that it is an event sponsor of the BroadSoft Connections 2017 user conference, which takes place October 22-25 at the JW Marriott Phoenix Desert Ridge Resort & Spa in Phoenix, AZ. During the event, Edgewater Networks will feature demonstrations of the latest end-to-end network interoperability capabilities, including Zero Touch Provisioning, UC Analytics from the core to the endpoint, SD-WAN optimized for BroadSoft, and much more. Continuing a long-standing partnership with BroadSoft, Edgewater Networks has completed another level of BroadCloud certification, this time for local survivability which is critical for business continuity for SMB and Enterprise customers. BroadSoft’s PacketSmart is available on all EdgeMarc Intelligent Edges. All elements of the Network Edge Orchestration are
More than 70 Companies to Showcase Top Tech at CES Unveiled Paris20.10.2017 15:08 | Pressemelding
The Consumer Technology Association (CTA) today announced that more than 70 exhibitors will showcase their latest innovations at the now sold-out fifth annual CES Unveiled Paris The event will focus on the Internet of Things (IoT), connectivity and smart cities, and draw more than 600 attendees. CES Unveiled Paris will run from 2-7:30 PM on Tuesday, October 24, 2017 at the Palais Brongniart. Regional technology companies, top-tier media outlets, buyers and key industry influencers will come together at CES Unveiled Paris to get a direct look at the latest industry developments. The day kicks off with a CES news conference and CTA market trends presentation. Conference programming is followed by a tabletop exhibition & networking reception. Curated exhibitors will be there to showcase top tech from robotics and audio to smart home and augmented and virtual reality. Notable
Westinghouse Receives Regulatory Approval for Analysis Methodologies20.10.2017 12:15 | Pressemelding
Westinghouse Electric Company today announced that it has received approval from the U.S. Nuclear Regulatory Commission (NRC) for two new important analysis methodologies that will be used to upgrade Westinghouse- and Combustion Engineering-based nuclear steam supply system (NSSS) safety analyses. The approvals granted are for the new FULL SPECTRUMTM Loss of Coolant Accident (FSLOCATM) methodology and the Performance Analysis and Design Model software code update, PAD5. FSLOCA is capable of improved modeling of the transient response in a pressurized water reactor to the full spectrum of LOCA break sizes that could occur, and PAD5 is the next generation of the Westinghouse fuel rod design performance code. “These codes were developed to work in concert with each other to maximize analytical margin for nuclear utilities,” said Michele DeWitt, senior vice preside
Gilead Announces Multiple Scientific Presentations Demonstrating High Cure Rates in Difficult-to-Cure HCV Patients and Improved Long-Term Bone and Renal Safety of Vemlidy® in HBV Patients Switched from Viread®20.10.2017 12:03 | Pressemelding
Gilead Sciences, Inc. (NASDAQ: GILD) today announced results from Phase 2 and Phase 3 studies of its approved medicines for chronic hepatitis C virus (HCV) and hepatitis B virus (HBV) infection, adding to the body of evidence supporting Gilead’s viral hepatitis therapies in diverse patient populations. These and other data from more than 25 abstracts will be presented this week at The Liver Meeting® 2017, which begins today in Washington, D.C. Positive results from studies of Harvoni® (ledipasvir 90mg/sofosbuvir 400mg) in HCV-infected patients with severe renal impairment, Epclusa® (sofosbuvir 400mg/velpatasvir 100mg) in HCV-infected liver transplant recipients and Vosevi® (sofosbuvir 400mg/velpatasvir 100mg/voxilaprevir 100mg) in NS5A-inhibitor experienced HCV-infected patients will be presented during poster sessions on October 21 and October 22. In addition, updated results f
Schlumberger Announces Third-Quarter 2017 Results20.10.2017 11:00 | Pressemelding
Schlumberger Limited (NYSE:SLB) today reported results for the third quarter of 2017. (Stated in millions, except per share amounts) Three Months Ended Change Sept. 30, 2017 Jun. 30, 2017 Sept. 30, 2016 Sequential Year-on-year
SP3H Announces That It Has Obtained a €1.2 Million European Union Grant for Its Intelligent and Clean Vehicle (VIP) Project20.10.2017 10:47 | Pressemelding
SP3H is proud to announce joining the very select circle of the 10 French winners of the H2020 SME Instrument Phase 2 program since 2014. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171020005325/en/ Last summer VIP received the very prestigious SME instrument phase 2 H2020 label in the "transport & smart cities mobility" category. With an overall budget of € 1.7 million, VIP is subsidized by the European Union at a rate of 70% or €1.2 million. The framework contract was officially signed early October. VIP is the pre-industrialization program for Fuelbox sensors, the world's first miniaturized scanner capable of analyzing the quality of fuels on board vehicles. The heart of the program remains closely linked to the reduction of CO2 and pollutant emissions from vehicle
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom